. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: J Pharmacokinet Pharmacodyn. 2020 Apr 22;47(3):199–218. doi: 10.1007/s10928-020-09684-2

Table 8.

Conventional model evaluation metrics for the previously developed pediatric clindamycin PBPK model [9]

Variable	1 month–2 years	2–6 years	6–18 years	All
Number of subjects	10	6	13	29
Number of PK samples	48	37	72	157
ME (mcg/mL)	−0.82	1.7	0.06	0.18
RMSE (mcg/mL)	4.2	5.68	6.45	5.66
AFE	1.31	0.73	0.98	1.00
AAFE	1.84	1.76	2.14	1.95
Number of samples outside the model’s 90 PI (N [%])	3 (6.25 %)	6 (16.22 %)	27 (37.5%)^*	36 (22.93 %)^a,^*

ME, mean error; RMSE, root mean squared error; AFE, average fold-error; AAFE, average absolute fold-error; PBPK, physiologically-based pharmacokinetic; PI, prediction interval.

Summary of age-segmented analyses.

Proportion of observed data exceeding model’s 90% PI is statistically greater than 0.10 (p-value<0.05, exact binomial test)